It can be a pain, but insulin shots are a necessity for millions. And it's something Kerby Bennet is trying to avoid. A few years ago, her twin sister Taylor was diagnosed with type-one diabetes.
"It was a shock to us, especially because she was 17 when she was diagnosed," Bennet said.
Because her identical twin has it Kerby has a 65-percent chance of developing the disease too. Now, she's the first person to enroll in a clinical trial at Vanderbilt Univerisity testing the drug Teplizumab.
"It's been well studied in individuals who have been newly diagnosed with diabetes. What if we take someone who is at high risk to develop diabetes, can we actually prevent it?" Dr. William Russell, director of Pediatric Endocrinology and Diabetes at Vanderbilt University, said.
The drug battles an immune system protein called cd-3. The goal is to find out if it can also stop the destruction of the insulin-producing cells in the pancreas before diabetes occurs.
Meanwhile, researchers at the University of Colorado are curing it in animals. By isolating the specific t-cells that attack the pancreas they developed a drug that can stop diabetes from developing and even reverse it in mice that already have it.
Kerby hopes the drugs will help prevent her from developing diabetes and someday cure her twin sister.
"I think research like this makes it possible," Bennet said.
Researchers will follow Kerby for up to four years. Doctors say their ultimate goal for the trial is to enroll 150 people in the u-s and at a few foreign sites.
Trial Info: http://www.diabetestrialnet.org/
Get Eyewitness News Delivered